Vicplas reported 1H2026 revenue of SGD 62.4 million, up 15%. The company posted a net loss after tax of SGD 3.4 million. Medical devices revenue rose 11% to SGD 39 million, while segment result was a loss of SGD 5.65 million due to higher operating costs tied to the Mexico plant ramp-up and new projects in Singapore and Mexico. Pipes and pipe fittings revenue increased 21% to SGD 23.41 million, and segment result rose 60% to SGD 5.69 million on robust construction activity in Singapore. Group adjusted EBITDA fell 27% to SGD 3.2 million, and CEO Walter Tarca said medical devices revenue is expected to improve as new projects are commercialised and Mexico contributes more, though near-term segment results will remain constrained as utilisation ramps up.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicplas International Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: MC9L7THCBZIP2CST) on March 13, 2026, and is solely responsible for the information contained therein.
Comments